Marker to Present at Two Upcoming Cellular Therapy Conferences

Houston, Texas – Octerber 18, 2018Marker Therapeutics, Inc. (NASDAQ: MRKR), a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter L. Hoang, will participate at two upcoming cellular therapy conferences.  Mr. Hoang will present a talk titled, “Moving Beyond CAR-T: Non-Engineered Multi-Antigen Specific T Cells Can Drive Significant Therapeutic Benefit for Patients with Lymphoma, Myeloma, and AML,” at the PDA Cell and Gene Therapy Conference, to be held October 23, 2018, in Bethesda, MD, and will participate on a panel titled, “Future of Cellular Therapy – The ‘Living Drug,’” at the offices of Mintz Levin on October 25, 2018, in New York City. PDA Cell and Gene Therapy Conference: Presentation Title: Moving Beyond CAR-T: Non-Engineered Multi-Antigen Specific T Cells Can Drive Significant Therapeutic Benefit for Patients with Lymphoma, Myeloma, and AML Date: Tuesday, October 23, 2018 Location: Hyatt Regency Bethesda; Bethesda, MD Time: 4:00pm (ET): Presentation | 5:00pm (ET): Discussion Panel   Panel Title: Future of Cellular Therapy – The “Living Drug” Date: Thursday, October 25, 2018 Location: Mintz Levin Offices, New York, NY Time: 5:30pm (ET)[/vc_column_text][vc_empty_space height=”4px”][vc_column_text][mrkrdisclaimer]